Barclays lowered the firm’s price target on Sotera Health (SHC) to $17 from $18 and keeps an Overweight rating on the shares. Sentiment remains very bearish on the life science tools group from a focus on National Institutes of Health funding cuts impacting demand, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHC: